Woodline Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.74M Buy
+150,302
New +$6.93M 0.03% 547
2025
Q3
Sell
-43,380
Closed -$1.36M 1068
2025
Q2
$1.36M Buy
+43,380
New +$1.42M 0.01% 774
2025
Q1
Sell
-39,938
Closed -$1.57M 1053
2024
Q4
$1.57M Buy
+39,938
New +$1.65M 0.01% 693
2024
Q1
Sell
-196,453
Closed -$9.05M 649
2023
Q4
$9.05M Buy
196,453
+53,002
+37% +$1.87M 0.1% 242
2023
Q3
$4.9M Sell
143,451
-146,949
-51% -$5.5M 0.06% 312
2023
Q2
$11.2M Sell
290,400
-129,629
-31% -$5.15M 0.13% 194
2023
Q1
$15M Buy
420,029
+121,589
+41% +$4.49M 0.21% 141
2022
Q4
$11.8M Sell
298,440
-105,919
-26% -$3.86M 0.16% 182
2022
Q3
$14.6M Buy
404,359
+175,431
+77% +$6.31M 0.21% 147
2022
Q2
$6.96M Buy
+228,928
New +$6.92M 0.11% 216
2021
Q4
Sell
-199,984
Closed -$3.06M 798
2021
Q3
$3.06M Buy
+199,984
New +$3.48M 0.05% 334

Other funds holding XENE